Home › Compare › BDOUF vs ABBV
BDOUF yields 3.44% · ABBV yields 3.06%● Live data
📍 BDOUF pulled ahead of the other in Year 2
Combined, BDOUF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BDOUF + ABBV for your $10,000?
BDO Unibank, Inc., together with its subsidiaries, provides various banking products and services primarily in the Philippines. Its deposit products include savings, checking, and time deposit accounts; and loan portfolio comprises personal, auto, home, small and medium-enterprise, project finance, term, and working capital loans. The company also offers life, auto, home, personal accident, travel, and employee benefits insurance products; remittance services; trade facilities, such as trade settlements, trust receipts, export bill purchases, and letters of credit; and trust and investment services consisting of unit investment trust funds, portfolio management, escrow services, security/collateral/ bond trusteeship, facility/paying agency, and investment advisory services. In addition, it provides investment banking services, such as equity and fixed income underwriting, financial advisory, direct equity investment, securitization, and retail treasury bonds services. Further, the company offers leasing and financing solutions, including direct leases, sale and leaseback arrangements, car, equipment, vehicle leasing, and cash management services; treasury services; debit and credit cards; and mini pos, online, mobile, and phone banking services. As of December 31, 2021, it operated 1,193 branches, including 2 foreign branches; 4,152 automated teller machines (ATMs); 624 cash accept machines; and 9 self-service teller machines. BDO Unibank, Inc. was incorporated in 1967 and is headquartered in Makati City, the Philippines.
Full BDOUF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.